9999999997-11-014919.txt : 20110901 9999999997-11-014919.hdr.sgml : 20110901 20110901152743 ACCESSION NUMBER: 9999999997-11-014919 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110901 DATE AS OF CHANGE: 20110901 20110901 20110901 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 000-16929 FILM NUMBER: 111070936 BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE C-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE C-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Q(#`@;V)J#3P\+TQI;F5AF4@-30O5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R`A(,4X`$XPT@P1(&)-AU@<0G;08F1H8=(%D&1G3B/^/L/P`!!@"SE@;D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@ M("`@#0HU,R`P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF``*>6@94P,@` MDN5H0!9C@6(&AAL,W`R7!E+U!A9V4^/@UE;F1O8FH--#0@,"!O8FH-/#PO1FEL=&5R+T9L871E M1&5C;V1E+T9I M3*>3K,E71"7.^.[Q\I)>-\N\;`EG(J'3[.E37JPW+4D223_DG>I",D-GVVS= M$*GHK"K;R:3Z]7"AM44=$8PQ#/"(VEFV*[8O[Q;%+F_(;?Z3W%6[K'R/NMML MEU/4.`7*O\XO)M5V]66!^GE;Y^UR0V^K>I=M473?9608HS=MMBV6U^5ZFQ-& MYVV^^T:X3.CBY2E'6TBY+I[:JJ;?^TJ4-E=7KDZH&TR.??UCN:Q61;FF]T5Y M739%>)\5==-.-UGM/KG_#>BVZR+]G/4&0FLZ?_[10CJ+^CG'O$)R+O*JW30/ MQECR+P&C(:4D6KO1<#>G\?;/=V[EWK9"\.%A('E5%1VO*0&";IG)4+ M[)^Q//CT9]N?O3[XN$1EI,.D^@:@/E5$"(9/#4_=-T='>?@;B#O7"5S4\`(N M6)(>W.,0/G1G'+SZ!"$QL%!])\4H`0](UN=@'&M(KS.##(L#F=L`T$O?5..: MH(:)Z>2=O]$#='1)8X0;Q)&(@(5$"$X'9AR2]2,R!HQ/N,D#`!MHTA@P!3'" M)!R*H]*]20D8?!Z1E@+].H[]2_I-]NF7F7/H]PW654=8U[+3I*OL2=(]DV_= M']I_S+>*#=0);`(Z;D=KG*BSZ3;,I8OA`7.;"KZW3_$.^)W`'/J=`IV-]LO; M@2_2+>=!%VBY]XO95B5I(!)DV9X1`S-&Y!/OE/`[?.COQ.45]V3,MLKU4\#9 MP@[R@VP+=J?9%JI'LN7\%=EZ-GA%MJD]@VNC#$P"I2=A#+SL%-YEK_F M6A5=T1A0J/_GC>&+]3CFC^U/CL?WE'>(3@'P[3^FVF/P5'LC&%87'[T_BK> MPY&@),#]J<@S'!VS,K)GTY&*]ND!G"TCD2;=P^&DA%]Z?LPGGVZN/3_D!4YH M1,LDP,;3"T;3/ST9\,DOGA_Q\?2=9_:RR>^X\L'S,W@HO9UVTH.F)#'M.7/8 MA=BZD(@LZED;\3LOXH\X:+P0)J!_[XR/$1[3O5RR'_,J=7V$@5'PJK3+H%FWDBC;!PZ!N M8(E8A48J";&0XB3'&9`+8C/F]0H,+[V,?T$@5@C+\GF$Z;V&Q0K6%O`3/4\2 M.&4P0[(E*4=M(1@6QY'(L@%N(`* MN8]/#(,TL)!H,&#"V#OC,LD)NBIG_02)U#A%6@(1AETG*;A6K=8[XQ//S_G5 M3Z1I[UCE@#SCB@X%3V;,$G:1"GHELM10@)12A=?MD3L7O$OV[)51QN ML"VVYU44$\V<&(&ZNH<]):DG,ZI6%BVE8!J4[L?&5[%(=FJD>8*2Q@!A1)KU MG0E0P^ZQU&&$[UF):WH%PHA+:Y(O48("6C8,]S[C^P4,5IB`I:>X#KZU:49: MGHSN-6L>C`AP9JAW/WC@6HFY*QO,)&MJFS%V!0QCC5JSK%\6"=Z"#I?CKWJ> MJF[=6$"B56&/*98,4MW"+12QJ\OW$'UI<_S="R$_2ML"8*6R#Z7HW$"XTD0# MK1K_B8%R2_:*9D\DW1-Q]?362PD$A*'6"<2.1=KCD^>G+=!:!/5AOB$GF6,I MVS--C<%-!/S^WN5#%\R]LOZADO9=:S(#5-E@7WU`O?.F7ZRYD+VD[E,"X`R@ M51*>.F!6!['\%1X(7UQ>E2A9(D1I\QQMH)&.C%)P>J>>$/M6$>VT-4!559)* M9H765&]/>"?`)?.60N1*CY14?9_AU+Q+4!3*'@EH_D!DUPX"ZT.IWF$T>O%` MS$6[KLA"F\_>_"D843#4=?<"THQSO^E)P'<'JZM)7UDXB,]]VQ$ M;W7<7%1)]P/YZ6J+4;P:RQ7.9[U55UY5-T00VL2:/6YOVY)8Z"P1?ZC`@`D* M>L:7K>T+F\K:U:I.*FD4S$64&@,:H3=79"PU#MQNSAC1*D,MSZZ=D/KM4EO< M`JXTTL8'I")N-]`]JWH@*VZ0.>@S\6Y18GW>&\A#I2YQ^55/:R1D-'AQ;+^3 M%#3/[.3W1'ZL&1V?S.!C2/9QD&F0P0>*[@><6F7DKF%:@Q1!X\+]P"GW(>8G?2T'0.4< M[5Z`.I>G">9==Q3J-FI8=!(N9YWJ7C)<+K5@"#3+&-2_MU=(Q6) MS?LKD_?!SU/E/D_]5.3IJ<)0ZN1%3H6G1:(?+Z\75Z&^I57NTL#>X;7GT5T& MF;Y-^KK]4VUM*'ZIR(9#%;Y!@9 M$1FEP'Z>@8V!F0$,$I.+"QP#`GQ`[+S\O%0&#/#M&@,CB+ZL"S(+4QXO8$TN M*"H!T@>`V"@EM3@92'\!XLSRD@*@.&,"D"V2E`UF@]2)9(<$.0/9'4`V7TEJ M!4B,P3F_H+(H,SVC1,'0TM)2P3$E/RE5(;BRN"0UMUC!,R\YOZ@@ORBQ)#4% MJ!9J!PCPNQ`P8A0[CQ!#@.32HC(H MDY')F($!(,``2<8X+PT*96YDPJ> MBE!2")2"4&!*$2&4$B)2Y1$%?D*45)4((&I$134C:JH+(8!J@#F`AY^9D3'2 MW.!301RQ@"^)"Z0DXGG!LB).R+HFKK"R>.(:609L#UDS"7@"B(`G1:1Y%U(5 M).!%[$?`BS&1@!<3C@5>X7$P\(KHZ>+"W>#(GK9NTXRYF_9CSCC^WQ/K_#+= MY%<*;ML_YB_-`#5SQ_YUR&XWC:?#TK;M^VFUFI&WL(6&V=82HA$U"HU2(VE4 M&@MXMK6$4E@IK!16"BN%E<)*8:6P4D0IHA11BBA%E")*$:6(4F2AW+D-+=-N MYW;YH"=;GYZ>;YFG%RU^WQ-&;WL6V.8_/T M-AS[X:H9?@T_=??X-[OU_+F&O=^CS]UCV^7=0P/#Y^ZOIVF>TU5@O?V1^]-T M'IZ^/Q_&=G@;#GG\1M]DWB]5I7-JIC5:%8+LUJ:U616*[-:VS;>D67;"K:N8/L*MK!@&PNVLF`[ M"[:T8%MCVQJ_\\9L:VQ;8]L:V];8ML;_M/93@`$`^I&FMC.60B/SX*/'@Z>&UP;65T82!X;6QN M#IX;7!T:STB061O8F4@6$U0($-O&UP M.DUE=&%D871A1&%T93XR,#$Q+3`Y+3`Q5#$U.C(T.C0Y+3`T.C`P/"]X;7`Z M365T861A=&%$871E/@H@("`@("`@("`\>&UP.D-R96%T;W)4;V]L/D%C&UP34TZ26YS M=&%N8V5)1#YU=6ED.F8S,S8S9#0Y+3)C8C0M-#@P.2TY.&4X+35A-#8X-V0Y M-CAD8SPO>&UP34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AM<$U-.G-U8FIE M8W0^"B`@("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\7=O#I3;W5R8V5-;V1I9FEE9#X*("`@("`@("`@/'!D9G@Z0V]M M<&%N>3Y396-U&AA;F=E($-O;6UI3X*("`@("`@("`@/'!D9G@Z0V]M;65N=',^5F5R M[&:7"$9*H;AZT4*AHN=L,FVC-B.3!-VW=U9$/'@9?H9OOI\Q&C2L5NVFEA.Q MJKEI;^A\QE2R>D+.D1)T2_V]?7=I4GOTE6.)F,&E`+>?)Y>."/-1S#,N**,K MD@974`W7O>XZ;65<]L9<76BST'KQ0TGEQC.-KL!NN-NZ5V2PRPX.Q/!,')KV M'JI1G(%&G(WP$$=V/(E4?MA398^BB8>(X:_']J:W M`M3Q!7V1KL=8WE`UZ_67``,`BTE86PT*96YDF4@-#$O M5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F(``B9&_FP&)@:F."`A M>`E(,/:!"#.@Q)U%0!8#`^/@)I@>``E&!H```P`-?059#0IE;F1S=')E86T- >96YD;V)J#7-T87)T>')E9@T*,3$V#0HE)45/1@T* ` end